Portfolio Manager Factsheet
General market gyrations have been dictating share price movements in the biotech sector more than company fundamentals. Biogen shares rebounded following an update from their partner Eisai for their Alzheimer’s treatment BAN2401 in late October.
The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.